SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 21st, 2023 • Moleculin Biotech, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 21st, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of December 20, 2023, between Moleculin Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT MOLECULIN BIOTECH, INC.Common Stock Purchase Warrant • December 21st, 2023 • Moleculin Biotech, Inc. • Pharmaceutical preparations
Contract Type FiledDecember 21st, 2023 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_______] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Shareholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on five (5) year anniversary of the Shareholder Approval Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 21st, 2023 • Moleculin Biotech, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 21st, 2023 Company Industry Jurisdiction
PREFUNDED COMMON STOCK PURCHASE WARRANT MOLECULIN BIOTECH, INC.Prefunded Common Stock Purchase Warrant • December 21st, 2023 • Moleculin Biotech, Inc. • Pharmaceutical preparations
Contract Type FiledDecember 21st, 2023 Company IndustryTHIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full] (the “Termination Date”) but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).